Cantor Fitzgerald Forecasts Cabaletta Bio FY2026 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Cabaletta Bio in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings of ($0.95) per share for the year. The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share.

CABA has been the subject of a number of other reports. UBS Group dropped their target price on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Guggenheim raised their target price on shares of Cabaletta Bio from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Wells Fargo & Company decreased their price target on Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 1st. Morgan Stanley lowered their price objective on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating for the company in a research note on Tuesday, April 1st. Finally, HC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of Cabaletta Bio in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Cabaletta Bio currently has an average rating of "Buy" and an average target price of $20.33.

Cabaletta Bio Trading Up 1.1%

Shares of NASDAQ:CABA traded up $0.02 during midday trading on Wednesday, hitting $1.77. The stock had a trading volume of 2,641,612 shares, compared to its average volume of 1,632,511. Cabaletta Bio has a 1 year low of $0.99 and a 1 year high of $13.50. The stock has a 50 day moving average price of $1.52 and a two-hundred day moving average price of $2.03. The company has a market capitalization of $89.82 million, a PE ratio of -0.82 and a beta of 2.81.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last posted its earnings results on Wednesday, May 21st. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.04).

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CABA. Two Sigma Advisers LP boosted its stake in shares of Cabaletta Bio by 195.8% during the 4th quarter. Two Sigma Advisers LP now owns 831,900 shares of the company's stock worth $1,888,000 after acquiring an additional 550,700 shares in the last quarter. BIT Capital GmbH acquired a new stake in shares of Cabaletta Bio in the fourth quarter valued at about $431,000. Renaissance Technologies LLC bought a new position in shares of Cabaletta Bio in the fourth quarter worth about $522,000. Two Sigma Investments LP grew its holdings in Cabaletta Bio by 78.8% in the 4th quarter. Two Sigma Investments LP now owns 751,894 shares of the company's stock valued at $1,707,000 after buying an additional 331,417 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Cabaletta Bio by 89.7% during the 4th quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company's stock valued at $2,874,000 after purchasing an additional 598,607 shares during the last quarter.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.